Promising new antibiotic targets potentially deadly gut infections

April 12, 2013

(Medical Xpress)—Researchers at the University of Virginia School of Medicine have developed a promising new antibiotic to treat potentially deadly gastrointestinal infections without harming the beneficial probiotic bacteria that help prevent relapse.

The investigational drug, Amixicile, can take down even hyper- of drug-resistant Clostridium difficile – commonly called "C. diff" – which kills 14,000 Americans each year. It also shows efficacy against Cryptosporidium (protozoans that cause diarrhea) and in mouse models of infection and potentially against many other human pathogens, including Campylobacter jejuni.

"You have an enzyme found in all these bad-guy bacteria, and our drug gets all of them," U.Va. researcher Paul Hoffman said. "It's remarkable to have one drug that has this kind of spectrum."

Because of Amixicile's expansive reach, Hoffman called it a "superdrug." It is so widely effective, he explained, because it targets enzymes shared by the .

"Most of the bad pathogens have this enzyme, and the good guys don't," Hoffman said. "The is absolutely the same in every one of these [harmful] organisms, so the way the drug works is the same for all these organisms, even though their enzymes are slightly different."

Recently completed preclinical studies show Amixicile has excellent safety and bioavailability indicators and is a good candidate for clinical trials, Hoffman said.

Amixicile could prove to be an important weapon against Clostridium difficile, an infection that often follows and strikes more than 400,000 people in the United States each year.

Amixicile offers significant advantage over existing treatments in its ability to spare the that help prevent a recurrence of the infection. In addition, high doses of Amixicile caused no adverse effects in mice, the U.Va. researchers reported.

"It's a very, very low toxicity drug," Hoffman said. "Best of all, we have not seen any indication of drug resistance, perhaps due to its novel mechanism of action.

"It has about every metric you could want in an antibiotic."

Hoffman and his fellow U.Va. researchers – including the School of Medicine's Dr. Richard L. Guerrant, Dr. Cirle Warren and Timothy L. Macdonald, who also holds a post in the College of Arts & Sciences' chemistry department – continue to work with the National Institutes of Health, the sponsor of the preclinical studies. The next step is to test the safety and effectiveness of Amixicile in humans, to see if it is as effective and well-tolerated as it has been in mice.

Hoffman and his colleagues are working closely with the U.Va. Licensing & Ventures Group to identify industry partners to assist in bringing the drug to market, so it may ultimately benefit patients.

Explore further: New antibiotic compound enters phase I clinical trial

Related Stories

New antibiotic compound enters phase I clinical trial

November 9, 2011
(Medical Xpress) -- Novacta Biosystems has commenced dosing of the first healthy volunteers in a phase I clinical trial of a new antibiotic to treat the hospital superbug Clostridium difficile.

Hope for powerful new C diff. treatment

September 19, 2011
MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly ...

Unnecessary antimicrobial use increases risk of recurrent infectious diarrhea

January 9, 2013
The impact of antibiotic misuse has far-reaching consequences in healthcare, including reduced efficacy of the drugs, increased prevalence of drug-resistant organisms, and increased risk of deadly infections. A new study ...

C. diff scientists reveal potential target to fight infections

November 30, 2012
Researchers at Virginia Bioinformatics Institute at Virginia Tech have discovered how a common diarrhea-causing bacterium sends the body's natural defenses into overdrive, actually intensifying illness while fighting infection.

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.